Profile data is unavailable for this security.
About the company
Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. It reconstructs prevalent immune-response molecules, such as antibodies from disease tissue and identify their corresponding antigens, offering new therapeutic targets.
- Revenue in USD (TTM)3.25m
- Net income in USD-92.26m
- Incorporated2020
- Employees155.00
- LocationAbsci Corp18105 Se Mill Plain BlvdVANCOUVER 98683United StatesUSA
- Phone+1 (360) 949-1041
- Fax+1 (302) 655-5049
- Websitehttps://www.absci.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals Inc | 3.64m | -202.11m | 459.10m | 285.00 | -- | 1.91 | -- | 126.09 | -0.7783 | -0.7783 | 0.0139 | 0.6639 | 0.0106 | 0.7239 | 2.20 | 12,775.44 | -58.57 | -24.41 | -63.55 | -29.01 | 92.47 | 98.49 | -5,550.87 | -84.92 | 11.49 | -11.96 | 0.2931 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| Ginkgo Bioworks Holdings Inc | 184.34m | -897.68m | 460.56m | 1.22k | -- | 5.42 | -- | 2.50 | -18.03 | -18.03 | 3.69 | 1.62 | 0.0941 | -- | 4.20 | 151,342.40 | -45.83 | -- | -50.04 | -- | 80.22 | -- | -486.98 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| Organogenesis Holdings Inc | 448.39m | -16.54m | 464.01m | 862.00 | -- | 1.76 | -- | 1.03 | -0.125 | -0.125 | 3.38 | 1.99 | 1.00 | 4.27 | 4.49 | 520,176.30 | -3.70 | 5.46 | -4.51 | 6.90 | 75.14 | 74.94 | -3.69 | 4.81 | 2.42 | 8.33 | 0.2001 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| GH Research PLC | -100.00bn | -100.00bn | 470.33m | 49.00 | -- | 2.37 | -- | -- | -- | -- | -- | 3.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -- | -- | -58.47 | -- | -- | -- |
| Cartesian Therapeutics Inc | 47.94m | -244.83m | 472.61m | 38.00 | -- | 628.56 | -- | 9.86 | -37.79 | -37.79 | 3.25 | 0.0315 | 0.1708 | -- | 9.86 | 1,261,526.00 | -87.23 | -43.66 | -94.16 | -66.84 | -- | -- | -510.72 | -136.35 | -- | -0.3505 | 0.00 | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Grail Inc | 109.74m | -2.88bn | 475.05m | 1.37k | -- | 0.1763 | -- | 4.33 | -99.94 | -99.94 | 3.91 | 86.80 | -- | -- | -- | 81,894.77 | -- | -47.45 | -- | -48.55 | 44.06 | -- | -2,627.35 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
| Absci Corp | 3.25m | -92.26m | 486.02m | 155.00 | -- | 2.19 | -- | 149.55 | -0.9331 | -0.9331 | 0.0327 | 1.95 | 0.0128 | -- | 2.03 | 20,967.74 | -36.20 | -- | -40.23 | -- | -- | -- | -2,838.89 | -- | -- | -129.46 | 0.0284 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Contineum Therapeutics Inc | 0.00 | -31.45m | 498.54m | 31.00 | -- | 2.29 | -- | -- | -1.24 | -1.24 | 0.00 | 8.46 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 25.52m | -91.22m | 515.90m | 116.00 | -- | -- | -- | 20.22 | -1.91 | -1.91 | 0.5133 | -0.5088 | 0.0821 | -- | -- | 219,956.90 | -29.34 | -31.35 | -35.57 | -35.69 | -- | -- | -357.53 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Altimmune Inc | 409.00k | -101.35m | 522.37m | 59.00 | -- | 3.42 | -- | 1,277.19 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Prime Medicine Inc | 591.00k | -217.44m | 526.94m | 234.00 | -- | 2.68 | -- | 891.60 | -2.16 | -2.16 | 0.0058 | 1.64 | 0.0022 | -- | -- | 2,525.64 | -80.45 | -- | -88.55 | -- | -- | -- | -36,791.71 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Chromadex Corp | 91.67m | 1.49m | 535.45m | 106.00 | 370.31 | 15.51 | 230.20 | 5.84 | 0.0189 | 0.0189 | 1.21 | 0.4521 | 1.67 | 3.05 | 23.51 | 864,792.40 | 2.70 | -42.11 | 4.08 | -65.14 | 61.45 | 59.68 | 1.62 | -30.64 | 2.35 | -- | 0.0004 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Kezar Life Sciences Inc | 7.00m | -98.57m | 542.84m | 58.00 | -- | 0.3599 | -- | 77.55 | -13.55 | -13.55 | 0.962 | 20.67 | 0.0316 | -- | -- | 120,689.70 | -44.47 | -32.54 | -47.84 | -34.09 | -- | -- | -1,408.11 | -4,308.11 | -- | -- | 0.0634 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| Verve Therapeutics Inc | 24.40m | -197.03m | 543.54m | 255.00 | -- | 1.07 | -- | 22.28 | -2.46 | -2.46 | 0.3033 | 6.01 | 0.0382 | -- | 8.45 | 95,670.59 | -30.87 | -- | -32.86 | -- | -- | -- | -807.62 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Absci Corp's reporting currency: US Dollar USD
44.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 12.58m | 11.08% |
| Redmile Group LLCas of 30 Jun 2024 | 8.25m | 7.27% |
| Fred Alger Management LLCas of 30 Jun 2024 | 7.26m | 6.39% |
| ARK Investment Management LLCas of 30 Sep 2024 | 6.34m | 5.58% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.91m | 4.32% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 4.16m | 3.66% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.95m | 1.72% |
| Marshall Wace LLPas of 30 Jun 2024 | 1.83m | 1.62% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.81m | 1.59% |
| Adar1 Capital Management LLCas of 30 Jun 2024 | 1.70m | 1.50% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
